Altered HCAR3 expression may underlying the blunted niacin responses of the psychiatric disorders and the risk of schizophrenia

Psychiatry Clin Neurosci. 2024 Feb;78(2):123-130. doi: 10.1111/pcn.13617. Epub 2023 Dec 1.

Abstract

Aim: Blunted niacin response (BNR) was an endophenotype of schizophrenia, but the underlying mechanism remains unclarified. The objective of this study was to verify whether genes associated with BNR pathway constitute the genetic basis and the pathological mechanism of BNR phenotypic psychiatric patients.

Methods: Two independent sample sets consisting of 971 subjects were enrolled in this study. A total of 62 variants were genotyped in the discovery set, then the related variants were verified in the verification set. The published PGC GWAS data were used to validate the associations between the variants and psychiatry disorders. RT-PCR analysis, eQTL data, and Dual-Luciferase Reporter experiment were used to investigate the potential molecular mechanisms of the variants underlying BNR.

Results: The results showed that two SNPs, rs56959712 in HCAR2 and rs2454721 in HCAR3 were significantly associated with niacin response. The risk allele T of rs2454721 could affect the niacin responses of psychiatric patients through elevated HCAR3 gene expression. These two genes, especially HCAR3, were significantly associated with the risk of schizophrenia, as identified in this study and verified using the published GWAS data.

Conclusion: HCAR3 is a novel schizophrenia susceptibility gene which is significantly associated with blunted niacin response in schizophrenia. In-depth investigation of HCAR3 is of great significance for uncovering the pathogenesis and propose new therapeutic targets for psychiatric disorders, especially for the BNR subgroup patients.

Keywords: blunted niacin response; niacin receptor; psychiatric disorders; risk genes; schizophrenia.

MeSH terms

  • Endophenotypes
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Niacin* / pharmacology
  • Niacin* / therapeutic use
  • Polymorphism, Single Nucleotide
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Receptors, G-Protein-Coupled / therapeutic use
  • Receptors, Nicotinic* / genetics
  • Receptors, Nicotinic* / therapeutic use
  • Schizophrenia* / drug therapy

Substances

  • Niacin
  • HCAR3 protein, human
  • Receptors, Nicotinic
  • Receptors, G-Protein-Coupled